Polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) by an international consensus panel, reflecting the complex hormonal nature of the condition and moving away from the misleading focus on ovarian cysts. The change aims to raise awareness and encourage more comprehensive care for those affected.
A global consortium of experts has reached consensus to replace the term polycystic ovarian syndrome (PCOS) with polyendocrine metabolic ovarian syndrome (PMOS), and has outlined a process for the change. The term PCOS has long been recognised as being inaccurate and potentially harmful.
The syndrome is the most common endocrine disorder in women of reproductive age, affecting more than 170 million people globally during their reproductive years. Characterised by insulin resistance and hyperinsulinaemia, it is associated with increased risk of cardiovascular and cerebrovascular events, type 2 diabetes and impaired glucose tolerance. Pregnancy-related complications include gestational diabetes and venous thromboembolism.
Despite its prevalence, the current name is misleading, implying the presence of pathological ovarian cysts and failing to reflect its diverse endocrine, metabolic, reproductive, psychological and dermatological features. This confusion can delay diagnosis and hinder effective communication between patients and healthcare professionals, contributing to dissatisfaction with care. The reproductive focus of the name may also reinforce stigma, particularly in contexts where fertility is highly valued.
As outlined in The Lancet, a rigorous process engaging people with PCOS, multidisciplinary healthcare professionals and organisations worldwide was undertaken to agree the new name. The approach prioritised scientific accuracy, cultural appropriateness, stigma avoidance and feasibility of adoption. Consensus on the term polyendocrine metabolic ovarian syndrome was built through a range of robust methods.
To support the widespread adoption of PMOS, a comprehensive global implementation strategy has been developed. This includes a three-year transition period, education, and alignment with health systems and disease classification. The authors hope that the term will be incorporated into the international guidance when it is updated in 2028.
The full consensus article can be read here.
Journal of
Diabetes Nursing
Issue:
Early View
Polyendocrine metabolic ovarian syndrome: the new name for PCOS
A global consortium of experts has reached consensus to replace the term polycystic ovarian syndrome (PCOS) with polyendocrine metabolic ovarian syndrome (PMOS), and has outlined a process for the change. The term PCOS has long been recognised as being inaccurate and potentially harmful.
The syndrome is the most common endocrine disorder in women of reproductive age, affecting more than 170 million people globally during their reproductive years. Characterised by insulin resistance and hyperinsulinaemia, it is associated with increased risk of cardiovascular and cerebrovascular events, type 2 diabetes and impaired glucose tolerance. Pregnancy-related complications include gestational diabetes and venous thromboembolism.
Despite its prevalence, the current name is misleading, implying the presence of pathological ovarian cysts and failing to reflect its diverse endocrine, metabolic, reproductive, psychological and dermatological features. This confusion can delay diagnosis and hinder effective communication between patients and healthcare professionals, contributing to dissatisfaction with care. The reproductive focus of the name may also reinforce stigma, particularly in contexts where fertility is highly valued.
As outlined in The Lancet, a rigorous process engaging people with PCOS, multidisciplinary healthcare professionals and organisations worldwide was undertaken to agree the new name. The approach prioritised scientific accuracy, cultural appropriateness, stigma avoidance and feasibility of adoption. Consensus on the term polyendocrine metabolic ovarian syndrome was built through a range of robust methods.
To support the widespread adoption of PMOS, a comprehensive global implementation strategy has been developed. This includes a three-year transition period, education, and alignment with health systems and disease classification. The authors hope that the term will be incorporated into the international guidance when it is updated in 2028.
The full consensus article can be read here.
Editorial: Neighbourhood diabetes nursing: local, proactive, integrated
Diabetes a key priority in strategy to reduce cardiovascular deaths
GLP-1 receptor agonists and beyond. Part 1: benefits in type 2 diabetes
New guidance on HCL devices for pregnant women with type 1 diabetes
ADA 2026 highlights: Therapies in development for type 2 diabetes, obesity, dyslipidaemia and liver disease
Latest news: Polyendocrine metabolic ovarian syndrome, teplizumab recommendation and promising findings for tegoprubart
NICE recommends first drug to delay onset of type 1 diabetes
Nicola Milne discusses how care is shifting to a more proactive, prevention-focused model.
22 Jul 2026
Better diabetes care central to reducing premature mortality.
15 Jul 2026
Therapies delivering broad metabolic benefits beyond glucose lowering.
14 Jul 2026
Safety of mother and baby at centre of NICE recommendations.
8 Jul 2026